|
| Author, year | Design | Number of eyes | Mean age (SD) (years) | Mean follow-up (SD) (months) | Diagnosis for study eyes (numbers (%)) | Phakic status for study eyes (numbers (%)) | Medication | Country/region |
|
| Rabiolo et al., 2019 [10] | Noncomparative, retrospective | 157 | 65.8 (13.9) | 25 (30.37) | POAG: 85 (54.1)
PACG: 11 (7.0)
Secondary glaucoma: 61 (38.9) | Pseudo: 140 (89.2); phakic: 16 (10.2); aphakic: 1 (0.6) | 5-Fu | Italy |
| Okka et al., 2019 [11] | Noncomparative, retrospective | 16 | 46 (18.2) | 12.22 (6.08) | POAG: 9 (56.3)
Secondary glaucoma: 7 (44) | N/A | 5-Fu | Turkey |
| Kim et al., 2019 [12] | Comparative, retrospective | 35 | 58.5 (13.1) | >6 (N/A) | POAG: 21 (60.0)
PACG: 3 (8.6)
Secondary glaucoma: 11 (31.4) | N/A | 5-Fu | South Korea |
| Than et al., 2018 [13] | Noncomparative, retrospective | 96 | 67 (15) | 37.08 (21) | POAG: 70 (72.9)
PACG: 6 (6.25)
Secondary glaucoma: 18 (18.75)
N/A: 2 (2.1) | Pseudo: 24 (25); phakic: 72 (75) | 5-Fu | UK |
| Pathak-Ray and Choudhari, 2018 [14] | Noncomparative, prospective | 39 | 59 (14.25) | 20 (11) | POAG: 9 (23.1)
PACG: 21 (53.8)
Secondary glaucoma: 9 (23.1) | Pseudo: 26 (66.7); phakic: 13 (33.3) | MMC | India |
| Lin et al., 2018 [15] | Noncomparative, retrospective | 44 | 73.7 (N/A) | 58.7 (N/A) | POAG: 29 (65.9)
PACG: 7 (15.9)
Secondary glaucoma: 8 (18.2) | Pseudo: 28 (63.6); phakic: 16 (36.4) | MMC | UK |
| Zheng et al., 2016 [16] | Noncomparative, retrospective | 33 | 68.67 (10.38) | 21.72 (18.72) | POAG: 21 (67.7)
PACG: 2 (6.5)
Secondary glaucoma: 8 (25.8)# | N/A | 5-Fu | Australia |
| Tulidowicz-Bielak et al., 2016 [17] | Noncomparative, retrospective | 121 | 67.38 (13.76) | 27.6 (N/A) | POAG: 121 (100) | Single needling: pseudo: 62 (51.2); phakic: 38 (31.4); multiple needling: unknown 21 (17.4) | MMC | Poland |
| Panarelli et al., 2016 [18] | Noncomparative, retrospective | 27 | 69.1 (13.1) | 54.2 (30.4) | POAG: 18 (66.7)
PACG: 2 (7.4)
Secondary glaucoma: 7 (25.9)
| Pseudo: 17 (63.0); phakic: 9 (33.3); aphakic: 1 (3.7) | MMC | USA |
| Liu et al., 2016 [19] | RCT | 75 | 48.5 (10.4) | 12 (N/A) | MMC : POAG: 14 (35.0) PACG: 23 (57.5)
Juvenile glaucoma: 3 (7.5) 5-Fu : POAG: 12 (34.3)
PACG: 20 (57.1)
Juvenile glaucoma: 1 (2.9)
Secondary glaucoma: 2 (5.7) | N/A | MMC/5-Fu | China |
| Lee et al., 2016 [20] | Comparative, retrospective | 41 | 52.1 (15.8) | 22.7 (9.4) | POAG: 8 (19.5)
PACG: 5 (12.2)
Secondary glaucoma: 28 (68.3) | Pseudo: 19 (46.3); phakic: 21 (51.2); aphakic: 1 (2.4) | 5-Fu | China |
| Tsai et al., 2015 [21] | Comparative, retrospective | 227 | 66.9 (11.2) | >6 (N/A) | POAG: 157 (69.2)
PACG: 70 (30.8) | N/A | 5-Fu | Singapore |
| Tatham et al., 2013 [22] | Comparative, retrospective | 34 | 67.88 (N/A) | 25.2 (1.2) | POAG: 21 (61.8)
PACG: 5 (14.7)
Secondary glaucoma: 8 (23.5) | Pseudo: 17 (50.0); phakic: 17 (50.0) | 5-Fu | UK |
| Suzuki and Susanna-Jr, 2013 [23] | RCT | 20 | 57.3 (15.21) | 12 (N/A) | POAG: 17 (85.0)
Congenital glaucoma: 1 (5.0)
Secondary glaucoma: 2 (10.0) | N/A | 5-Fu | Brazil |
| Dalvi et al., 2012 [24] | Comparative, retrospective | 40 | 67.83 (12.02) | 60 (N/A) | POAG: 28 (70.0)
PACG: 6 (15.0)
Secondary glaucoma: 6 (15.0) | Pseudo: 20 (50.0); phakic: 20 (50.0) | 5-Fu | Canada |
| Amini et al., 2012 [7] | Noncomparative, retrospective | 27 | 56.5 (16.2) | 20.31 (15.63) | POAG: 7 (26.0)
PACG: 4 (14.8)
Juvenile glaucoma: 4 (14.8)
Secondary glaucoma: 11 (40.7)
Developmental glaucoma: 1 (3.7) | N/A | MMC | Iran |
| Maestrini et al., 2011 [25] | Noncomparative, prospective | 125 | 61.6 (18.8) | 20.8 (12) | POAG: 97 (77.6)
PACG: 10 (8.0)
Congenital glaucoma: 6 (4.8)
Secondary glaucoma: 12 (9.6) | Pseudo: 53 (42.4); phakic: 69 (55.2); aphakic: 3 (2.4) | MMC | Brazil |
| Palejwala et al., 2010 [26] | Comparative, retrospective | 107 | 74.35 (11.95) | 10.55 (11.01) | POAG: 81 (75.7)
PACG: 3 (2.8)
Secondary glaucoma: 23 (21.5) | Pseudo: 48 (44.9); phakic: 58 (54.2); aphakic: 1 (0.9) | MMC/5-Fu | USA |
| Elsayed and El-Raggal, 2010 [27] | Noncomparative, retrospective | 30 | 7.3 (3.4) | 9.23 (5.25) | Congenital glaucoma: 30 (100) | N/A | MMC | Egypt |
| Kapasi and Birt, 2009 [28] | Noncomparative, retrospective | 37 | 71.2 (12.6) | 24 (N/A) | N/A | N/A | 5-Fu | Canada |
| Anand and Khan, 2009 [29] | Comparative, retrospective | 98 | 73.5 (11.1) | 53 (18.12) | 5-Fu: POAG: 45 (88.2)
PACG: 5 (9.8)
Secondary glaucoma: 1 (2.0)
MMC: POAG: 37 (841)
PACG: 4 (9.0)
Secondary glaucoma: 3 (6.9)# | MMC group: pseudo: 28 (62.2); phakic: 17 (37.8); 5-Fu group: pseudo: 30 (56.6); phakic: 23 (43.4) | MMC/5-Fu | UK |
| Zarei et al., 2008 [30] | Noncomparative, prospective | 33 | 45.67 (22.41) | 9.24 (5.27) | POAG: 9 (27.3)
PACG: 4 (12.1)
Congenital glaucoma: 6 (18.2)
Juvenile glaucoma: 4 (12.1)
Developmental glaucoma: 1 (2.7)
Secondary glaucoma: 9 (27.3) | N/A | MMC | Iran |
| Rotchford and King, 2008 [2] | Noncomparative, prospective | 81 | 70 (N/A) | 40.27 (N/A) | POAG: 56 (69.1) PACG: 8 (9.9) secondary glaucoma: 17 (21.0) | Pseudo: 27 (33.3); phakic: 54 (66.7) | 5-Fu | UK |
| Gutierrez-Ortiz et al., 2006 [31] | Noncomparative, prospective | 34 | 65.9 (8.3) | 14.2 (9.8) | POAG: 23 (67.6) PACG: 5 (14.7)
Juvenile glaucoma: 1 (2.9)
Secondary glaucoma: 5 (14.7) | N/A | MMC | Spain |
| Shetty et al., 2005 [32] | Noncomparative, retrospective | 44 | 72.9 (10.4) | >12 (NA) | POAG: 35 (79.5)
PACG: 4 (9.1)
Secondary glaucoma: 5 (11.4) | Pseudo: 31 (70.5); phakic: 12 (27.3); aphakic: 1 (2.3) | MMC | USA |
| Jacobs et al., 2005 [33] | Noncomparative, retrospective | 28 | 61 (N/A) | 14 (N/A) | N/A | N/A | 5-Fu | Belgium |
| Paris et al., 2004 [34] | Noncomparative, retrospective | 36 | N/A | 6 (N/A) | POAG: 36 (100) | N/A | 5-Fu | USA |
| Broadway et al., 2004 [35] | Noncomparative, retrospective | 101 | 69 (11) | 20.2 (NA) | POAG: 71 (70.2)
PACG: 5 (5.0)
Secondary glaucoma: 25 (24.8) | Pseudo: 16 (15.8); phakic: 12 (79.2); aphakic: 5 (5.0) | 5-Fu | UK |
| Ben-Simon and Glovinsky, 2003 [36] | Noncomparative, retrospective | 41 | 65 (17) | 6 (N/A) | POAG: 26 (63.4)
PACG: 2 (4.9)
Congenital glaucoma: 2 (4.9)
Secondary glaucoma: 11 (26.8) | Pseudo: 22 (53.7); phakic: 13 (31.7); aphakic: 6 (14.6) | MMC | Israel |
| Hawkins et al., 2002 [37] | Noncomparative, retrospective | 49 | 70.14 (13.74) | 19.9 (16.3) | POAG: 25 (58.1)
PACG: 8 (18.6)
Secondary glaucoma: 10 (23.3)# | Pseudo/aphakic: 32 (74.4); phakic: 11 (25.6) | 5-Fu | USA |
| Chang and Hou, 2002 [38] | Noncomparative, retrospective | 25 | 53.0 (13.2) | 8.32 (6.61) | POAG: 4 (16.0)
PACG: 4 (16.0)
Secondary glaucoma: 17 (68.0) | Pseudo: 12 (48.0); phakic: 6 (24.0); aphakic: 7 (28.0) | 5-Fu | China |
| Shin et al., 2001 [39] | Noncomparative, retrospective | 64 | 72.1 (9.5) | 44.2 (21.2) | POAG: 61 (95.3)
PACG: 2 (3.1)
Secondary glaucoma: 1 (1.6) | Pseudo: 10 (15.6); phakic: 51 (79.7); aphakic: 3 (4.7) | 5-Fu | USA |
| Kapetansky and Kapetansky, 1999 [8] | Comparative, retrospective | 30 | N/A | >6 (N/A) | N/A | N/A | MMC | USA |
| Allen et al., 1998 [40] | Noncomparative, retrospective | 32 | 63.9 (10.8) | 10.7 (2.9) | POAG: 20 (62.5)
PACG: 5 (15.6)
Secondary glaucoma: 7 (21.9) | Pseudo: 6 (18.8); phakic: 24 (75.0); aphakic: 2 (6.2) | 5-Fu | UK |
| Mardelli et al., 1996 [4] | Noncomparative, retrospective | 62 | 72 (15) | 9.9 (3.7) | POAG: 32 (51.6)
PACG: 9 (14.5)
Congenital glaucoma: 4 (6.5)
Secondary glaucoma: 17 (27.4) | Pseudo: 42 (67.8); phakic: 17 (27.4); aphakic: 3 (4.8) | MMC | USA |
| Greenfield et al., 1996 [41] | Comparative, retrospective | 63 | 72.3 (11.2) | 13.1 (8.1) | POAG: 32 (50.8)
PACG: 9 (14.3)
Secondary glaucoma: 22 (34.9) | Pseudo: 27 (42.9); phakic: 36 (57.1) | MMC | USA |
| Shin et al., 1993 [9] | Comparative, retrospective | 30 | 63.5 (14.5) | 15.5 (5.2) | POAG: 22 (73.3)
Secondary glaucoma: 8 (26.7) | Pseudo: 17 (56.7); phakic: 10 (33.3); aphakic: 3 (10.0) | 5-Fu | USA |
|
